Healthcare - Biotechnology - NASDAQ - US
$ 0.037
0 %
$ 453 K
Market Cap
-0.04
P/E
INCOME STATEMENT
0
REVENUE
-22.4 M
OPERATING INCOME
-19.8 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Bellerophon Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 65 K |
| Gross Profit | -65 K |
| Operating Expenses | 22.4 M |
| Operating Income | -22.4 M |
| Other Expenses | -2.55 M |
| Net Income | -19.8 M |
Income Statement
Millions
| Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||||
| Cost Of Revenue | 65 K | 0.1 | 0.1 | 0.3 | 0.4 | 0.4 | 0.4 | 0 | 0 | 0 | 0 |
| Gross Profit | 65 K | (0.1) | (0.1) | (0.3) | (0.4) | (0.4) | (0.4) | 0 | 0 | 0 | 0 |
| OPERATING INCOME | |||||||||||
| Operating Expenses | 22.4 | 20.2 | 26.3 | 17.5 | 27.9 | 24.6 | 23.8 | 46.6 | 59.8 | 62.0 | 46.2 |
| Selling, General and Administrative Expenses | 6.0 | 7.1 | 8.4 | 6.4 | 7.6 | 6.7 | 7.1 | 14.9 | 13.8 | 9.0 | 7.2 |
| Research and Development Expenses | 16.3 | 13.0 | 17.9 | 11.0 | 20.3 | 17.9 | 16.6 | 33.4 | 46.0 | 53.0 | 38.7 |
| Operating Income | (22.4) | (20.2) | (26.3) | (17.5) | (27.9) | (24.6) | (23.8) | (46.6) | (59.8) | (62.0) | (46.2) |
| PRE-TAX INCOME | |||||||||||
| Interest Income Expense | 0.1 | 5 K | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 0.1 | 0.6 | (0.6) | 2.4 | 25.3 | (30.2) | (0.5) | 0.4 | 79 K | 0 | 0 |
| Pre-Tax Income | (22.2) | (19.6) | (26.9) | (15.1) | (2.6) | (54.8) | (24.3) | (46.5) | (59.7) | (62.0) | (46.2) |
| NET INCOME | |||||||||||
| Tax Provision | (2.4) | (1.8) | (2.1) | (1.8) | (5.4) | 29.8 | (0.4) | 1.2 | 0 | 0 | 0 |
| Net Income | (19.8) | (17.8) | (24.7) | (13.3) | 2.8 | (54.8) | (23.8) | (46.5) | (59.7) | (62.0) | (46.2) |
| EPS | 2.08 | 1.87 | 3.17 | 2.95 | 0.65 | 21.1 | 23.7 | 56.8 | 5.01 | 4.8 | 3.58 |